Publications in collaboration with researchers from Hospital General Universitario Gregorio Marañón (9)

2023

  1. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089

  2. Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study

    PLoS ONE, Vol. 18, Núm. 5 May

  3. SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2718-2731

  4. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

    Therapeutic Advances in Medical Oncology, Vol. 15

2022

  1. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study

    Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100

2021

  1. SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 988-1000

2018

  1. Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis

    Journal of Geriatric Oncology, Vol. 9, Núm. 3, pp. 254-264

2016

  1. On the effect of triplet or doublet chemotherapy in advanced gastric cancer: Results from a national cancer registry

    JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 11, pp. 1379-1388

2013

  1. Management of thrombosis with bevacizumab in metastatic colorectal cancer

    Cancer and Chemotherapy Reviews, Vol. 8, Núm. 2, pp. 56-62